Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and ovarian cancer

26 Apr 2021

Abstract excerpt

BACKGROUND AND PURPOSE: Advances in the treatment of triple-negative breast and ovarian cancer remain challenging. In particular, resistance to the available therapy, by restoring or overexpressing the DNA repair machinery, has often been reported. New strategies to improve the therapeutic outcomes of these cancers are needed. Herein, we disclose the dregamine 5-bromo-pyridin-2-ylhydrazone (BBIT20), a natural...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33899955
DOI: 10.1111/bph.15506

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BBIT20 inhibits homologous DNA repair with disruption of the BRCA1–BARD1 interaction in breast and ovarian cancerPMID 33899955Read ↗

A first-in-class inhibitor of homologous recombination DNA repair counteracts tumour growth, metastasis and therapeutic resistance in pancreatic cancerSemantic proximity Read ↗

BET proteins regulate homologous recombination‐mediated DNA repair: BRCAness and implications for cancer therapySemantic proximity Read ↗

DNA damage response inhibitors: An avenue for TNBC treatment.Semantic proximity Read ↗

Berberine attenuates XRCC1‐mediated base excision repair and sensitizes breast cancer cells to the chemotherapeutic drugsSemantic proximity Read ↗

Jab1 regulates HRR mRNA stability to modulate PARP inhibitor sensitivity in triple-negative breast cancerSemantic proximity Read ↗

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51Semantic proximity Read ↗

Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapiesSemantic proximity Read ↗

Total Synthesis and Chemoproteomics Connect Curcusone Diterpenes with Oncogenic Protein BRAT1Semantic proximity Read ↗

BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathwaysSemantic proximity Read ↗

Death effector domain-containing protein induces vulnerability to cell cycle inhibition in triple-negative breast cancerSemantic proximity Read ↗

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast CancerSemantic proximity Read ↗

Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.